--- title: "BUZZ-Astria 因其遗传疾病治疗获得 FDA 的孤儿药资格而股价上涨" description: "股票价格上涨约 3%，达到$11.45 美元，这是药物开发公司 Astria Therapeutics 的股价。该公司获得了美国食品药品监督管理局（FDA）授予纳维尼巴特用于遗传性血管性水肿治疗的孤儿药品认定。血管性水肿会导致手臂、面部、腿部和肠道肿胀。这一孤儿药品标签是基于早期到中期试验的结果，药物在 6 个月内每次一到两次剂量后，显示出每月肿胀发作率降低了 90% 至 96%。公司预计将在第四" type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/215642271.md" published_at: "2024-09-30T15:43:01.000Z" --- # BUZZ-Astria 因其遗传疾病治疗获得 FDA 的孤儿药资格而股价上涨 > 股票价格上涨约 3%，达到$11.45 美元，这是药物开发公司 Astria Therapeutics 的股价。该公司获得了美国食品药品监督管理局（FDA）授予纳维尼巴特用于遗传性血管性水肿治疗的孤儿药品认定。血管性水肿会导致手臂、面部、腿部和肠道肿胀。这一孤儿药品标签是基于早期到中期试验的结果，药物在 6 个月内每次一到两次剂量后，显示出每月肿胀发作率降低了 90% 至 96%。公司预计将在第四季度获得试验的额外结果，并计划在 2025 年第一季度将纳维尼巴特推进到后期试验阶段。考虑到本次股价变动，该股今年迄今上涨约 47.3% 药物开发公司 Astria Therapeutics (ATXS.O) 的股价上涨约 3%，至 11.45 美元 公司获得 FDA 对纳维巴特治疗遗传性血管性水肿的孤儿药指定 血管性水肿会导致手臂、面部、腿部和肠道肿胀 孤儿药标签基于早期到中期试验，药物一次或两次剂量在 6 个月内显示每月肿胀发作率降低 90% 至 96% 公司预计在第四季度从试验中获得额外结果，并计划于 2025 年第一季度将纳维巴特推进到后期试验阶段 包括本次股价上涨，股票今年迄今上涨约 47.3% ### Related Stocks - [ATXS.US - Astria Therapeutics](https://longbridge.com/zh-CN/quote/ATXS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Egetis Therapeutics Submits Emcitate NDA to FDA and Expects Regulatory Decision in September 2026 | Egetis Therapeutics AB has completed its rolling U.S. New Drug Application (NDA) submission for Emcitate® (tiratricol) a | [Link](https://longbridge.com/zh-CN/news/274995320.md) | | Astria Therapeutics to Be Acquired by BioCryst Pharmaceuticals | Astria Therapeutics is set to merge with BioCryst Pharmaceuticals, becoming a wholly owned subsidiary. A registration st | [Link](https://longbridge.com/zh-CN/news/270660274.md) | | Astria Therapeutics Reports Q3 2025 Results and BioCryst Acquisition | Astria Therapeutics, Inc. (ATXS) reported its Q3 2025 results, announcing its acquisition by BioCryst Pharmaceuticals, e | [Link](https://longbridge.com/zh-CN/news/265639741.md) | | Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema | Astria Therapeutics Inc. will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart for here | [Link](https://longbridge.com/zh-CN/news/263738231.md) | | Astria Therapeutics Reports Positive Phase 1b/2 Trial Results for Navenibart in HAE Patients | Astria Therapeutics Inc. reported positive results from the ALPHA-STAR Phase 1b/2 trial of navenibart (STAR-0215) for he | [Link](https://longbridge.com/zh-CN/news/264660894.md) | --- > **免责声明**：本文内容仅供参考，不构成任何投资建议。